Last reviewed · How we verify
Ying Qiao san
Ying Qiao san is a traditional Chinese medicine formulation that works to clear heat, resolve toxicity, and promote drainage of pus in acute inflammatory conditions.
Ying Qiao san is a traditional Chinese medicine formulation that works to clear heat, resolve toxicity, and promote drainage of pus in acute inflammatory conditions. Used for Acute bacterial infections with localized inflammation, Skin infections and abscesses, Lymphadenitis and related inflammatory conditions.
At a glance
| Generic name | Ying Qiao san |
|---|---|
| Sponsor | The University of Hong Kong |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Dermatology |
| Phase | FDA-approved |
Mechanism of action
This herbal formula combines multiple botanical ingredients traditionally used in Chinese medicine to address acute infections and inflammatory disorders. The mechanism is based on traditional Chinese medicine theory rather than modern molecular pharmacology, targeting what is classified as 'heat toxin' patterns. The formula is designed to support the body's natural immune response and promote resolution of localized infections.
Approved indications
- Acute bacterial infections with localized inflammation
- Skin infections and abscesses
- Lymphadenitis and related inflammatory conditions
Common side effects
Key clinical trials
- Trial of Chinese Herbal Medicine in the Treatment of Upper Respiratory Tract Infections (URTIs) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ying Qiao san CI brief — competitive landscape report
- Ying Qiao san updates RSS · CI watch RSS
- The University of Hong Kong portfolio CI